Prohías MJA

Language: Spanish
References: 27
Page: 1-8
PDF size: 194.42 Kb.

Text Extraction

No abstract.

REFERENCES

1. Corrales-Medina VF,Alvarez KN, Weissfeld LA et al. Association between hospitalizatión and subsequent risk of cardiovascular disease JAMA 2015; 313: 264-7

2. Cowan LT, Lutsey PL, Pankow JS, Matsushita K,Ishigami J, Lakshminarayan K. Inpatient and outpatient infection as a trigger of cardiovascular disease: the ARIC study. J Am Heart Assoc. 2018;7(22):e009683-e009683.

3. Madjid M, Aboshady I, Awan I, Litovsky S,Casscells SW. Influenza and cardiovascular disease:is there a causal relationship? Tex Heart Inst J. 2004;31(1):4-13

4. Guan WJ, Ni ZY, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine 2020.

5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24

6. Huang C,Wang Y,Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China Lancet 2020;395:497-506

7. Wu C, Chen X, Cai Y et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.

8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al. Clinical course and risk factor for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054- 1062.

9. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D and Gavazzi E. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. March 27, 2020. doi:10.1001/jamacardio.2020.1096. [epub ahead of print]

10. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 Mar 5 [Epub ahead of print]

11. Xiong TY ,Redwood.S, Prendergast B. Coronavirus and cardiovascular system: Acute and long term implications Eur Heart Journal. 2020

12. Fei Zhou TY, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. March 11, 2020. doi: 10.1016/S0140-6736(20)30566-3. [epub ahead of print].

13. M Bansal. Cardiovascular disease and COVID-19. Diabetes and Metab Sind Clin Research. 2020. 14.247-250

14. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. March 25, 2020. doi:10.1001/jamacardio.2020.0950. [epub ahead of print].

15. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 Mar 27

16. Lippi G, Lavie CJ and Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. March 10, 2020. doi:10.1016/j.pcad.2020.03.001. [epub ahead of print].

17. American College of Cardiology: Troponin and BNP Use in COVID-19. Available online at https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponinand-bnp-use-in-covid19. Last accessed April 6th 2020.

18. Chapman AR, Bularga A, Mills LN . High sensitivity Cardiac Troponin can be an Ally in the fight against COVID-19. Circulation. 2020

19. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The Variety of Cardiovascular Presentations of COVID-19.Circulation. April 3, 2020. doi 10.1161/CIRCULATIONAHA.120.047164. [epub ahead of print].

20. Silva Borba MG, Fonseca Almeida F, Souza Sampaio V. Effect of high vs Low dose of cloroquine diphosphate as adjuntive therapy for patients hospitalized with severe acute respiratory sindrome coronavirus. JAMA. Network Open 2020:3(4) e208857

21. Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 11: 413–426, 2014. doi:10.1038/nrcardio.2014.5

22. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020. 120. 046941.

23. Bozkurt B, Kovacs R and Harrington B. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. https://www.acc.org/latest-incardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-incovid-19 (accessed 17 March 2020)

24. Rico-Mesa JM, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI/ARB. Current Cardiology Report. 2020. 22:31

25. Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute síndrome coronavirus 2 infection. J Am Heart Assoc [Internet]. 2020 Apr 07

26. Fang L, Karakiulakis G and Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8: e21

27. Madjid M, Safani-Naeini P, Solomon SD. Potencial effects of Coronavirus on the Cardiovascular System JAMA Cardiology March 27 2020 e1-e9